SP
SIH Partners Portfolio holdings
AUM
$1.05B
This Quarter Return
+0.17%
1 Year Return
+21.73%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.14B
AUM Growth
+$1.14B
(-20%)
Cap. Flow
-$258M
Cap. Flow
% of AUM
-22.66%
Top 10 Holdings %
Top 10 Hldgs %
64.91%
Holding
282
New
168
Increased
28
Reduced
29
Closed
25
Top Buys
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
$124M |
| 2 |
Stellantis
STLA
|
$33.7M |
| 3 |
KraneShares CSI China Internet ETF
KWEB
|
$33.3M |
| 4 |
NetEase
NTES
|
$28.6M |
| 5 |
iShares China Large-Cap ETF
FXI
|
$27.1M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$263M |
| 2 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
$115M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
$108M |
| 4 |
UBS Group
UBS
|
$92.8M |
| 5 |
Logitech
LOGI
|
$31.8M |
Sector Composition
| 1 | Consumer Discretionary | 37.33% |
| 2 | Financials | 13.28% |
| 3 | Healthcare | 13% |
| 4 | Communication Services | 4.43% |
| 5 | Materials | 4.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Agilent Technologies
A
$35.5B
| $278K | 0.01% |
+2,375
| New | +$278K |
|
177
Suncor Energy
SU
$50.1B
| $275K | 0.01% |
+7,099
| New | +$275K |
|
178
Recursion Pharmaceuticals
RXRX
$2.02B
| $271K | 0.01% |
+51,202
| New | +$271K |
|
179
Endava
DAVA
$850M
| $263K | 0.01% |
13,505
| – | – |
|
180
DexCom
DXCM
$29.1B
| $254K | 0.01% |
+3,726
| New | +$254K |
|
181
PTC Therapeutics
PTCT
$4.16B
| $253K | 0.01% |
+4,962
| New | +$253K |
|
182
Hafnia
HAFN
$3.05B
| $249K | 0.01% |
59,838
+10,210
| +21% | +$42.5K |
|
183
IQVIA
IQV
$31.3B
| $244K | 0.01% |
+1,385
| New | +$244K |
|
184
Cameco
CCJ
$32.7B
| $235K | 0.01% |
+5,714
| New | +$235K |
|
185
Franco-Nevada
FNV
$36.7B
| $234K | 0.01% |
+1,483
| New | +$234K |
|
186
Consumers Staples Select Sector SPDR Fund
XLP
$15.8B
| $229K | 0.01% |
+2,805
| New | +$229K |
|
187
Arcellx
ACLX
$3.87B
| $227K | 0.01% |
+3,461
| New | +$227K |
|
188
Mettler-Toledo International
MTD
$26.3B
| $224K | 0.01% |
+190
| New | +$224K |
|
189
Idexx Laboratories
IDXX
$51.1B
| $224K | 0.01% |
+533
| New | +$224K |
|
190
Veracyte
VCYT
$2.37B
| $222K | 0.01% |
+7,500
| New | +$222K |
|
191
Avidity Biosciences
RNA
$6.07B
| $222K | 0.01% |
+7,533
| New | +$222K |
|
192
Rhythm Pharmaceuticals
RYTM
$6.93B
| $211K | 0.01% |
+3,980
| New | +$211K |
|
193
Ultragenyx Pharmaceutical
RARE
$3.09B
| $208K | 0.01% |
+5,738
| New | +$208K |
|
194
US Bancorp
USB
$75.4B
| $206K | 0.01% |
+4,887
| New | +$206K |
|
195
Canadian Imperial Bank of Commerce
CM
$71.8B
| $206K | 0.01% |
+3,652
| New | +$206K |
|
|
SWTX
196
DELISTED
SpringWorks Therapeutics
SWTX
| $204K | 0.01% |
+4,628
| New | +$204K |
|
197
Waters Corp
WAT
$17.6B
| $204K | 0.01% |
+553
| New | +$204K |
|
198
Akero Therapeutics
AKRO
$3.63B
| $203K | 0.01% |
+5,018
| New | +$203K |
|
199
Alvotech
ALVO
$2.48B
| $184K | 0.01% |
+19,000
| New | +$184K |
|
200
Immunovant
IMVT
$2.62B
| $183K | 0.01% |
+10,705
| New | +$183K |
|